Patents by Inventor Alexander A. Gall

Alexander A. Gall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040191796
    Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about (300) to about (800) nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyldiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10 [phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H, 3H, 7H, 9H, 10H)-tetrone structure.
    Type: Application
    Filed: June 25, 2003
    Publication date: September 30, 2004
    Applicant: EPOCH PHARMACEUTICALS, INC.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
  • Patent number: 6790945
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: September 14, 2004
    Assignee: Epoch Biosciences, Inc.
    Inventors: Eugeny A. Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M. J. Vermeulen
  • Publication number: 20040127436
    Abstract: The present invention provides compounds and methods for treatment of viral diseases and cancer.
    Type: Application
    Filed: September 24, 2003
    Publication date: July 1, 2004
    Applicant: Koronis Pharmaceuticals, Inc.
    Inventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev
  • Publication number: 20040116689
    Abstract: The invention provides compositions and methods for improved hybridization analysis utilizing DNA, RNA, PNA and chimeric oligomers in which one or more purine bases are substituted by a pyrazolo[5,4-d]pyrimidine or by a 7-deazapurine purine analogue. Reduced self-aggregation and reduced fluorescence quenching are obtained when the oligomers are used in various methods involving hybridization. Methods of synthesis, as well as novel synthetic precursors, are also provided.
    Type: Application
    Filed: November 4, 2003
    Publication date: June 17, 2004
    Applicant: Epoch Biosciences, Inc.
    Inventors: Alexander A. Gall, Igor V. Kutyavin, Nicolaas M.J. Vermeulen, Robert O. Dempcy
  • Publication number: 20040081959
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Application
    Filed: March 29, 2002
    Publication date: April 29, 2004
    Applicant: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
  • Patent number: 6727356
    Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about 300 to about 800 nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyldiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10-[phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H,3H,7H,9H,10H)-tetrone structure.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: April 27, 2004
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
  • Patent number: 6699975
    Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about 300 to about 800 nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyidiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10-[phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H,3H,7H,9H,10H)-tetrone structure.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: March 2, 2004
    Assignee: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
  • Patent number: 6683173
    Abstract: Modified oligonucleotides are provided containing bases selected from unsubstituted and 3-substituted pyrazolo[3,4-d]pyrimidines and 5-substituted pyrimidines, and optionally have attached minor groove binders and reporter groups.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: January 27, 2004
    Assignee: Epoch Biosciences, Inc.
    Inventors: Robert O. Dempcy, Alexander A. Gall, Sergey G. Lokhov, Irina A. Afonina, Michael J. Singer, Igor V. Kutyavin, Nicolaas M. J. Vermeulen
  • Publication number: 20030235822
    Abstract: Software systems and methods for predicting the melting temperature (Tm) and other characteristics of oligonucleotides, including modified oligonucleotides. Modified oligonucleotides are provided containing bases selected from unsubstituted and 3-substituted pyrazolo[3,4-d]pyrimidines and 5-substituted pyrimidines, and optionally have attached minor groove binders and reporter groups.
    Type: Application
    Filed: June 18, 2002
    Publication date: December 25, 2003
    Applicant: Epoch Biosciences, Inc.
    Inventors: Sergey G. Lokhov, Igor V. Kutyavin, Robert O. Dempcy, Alexander A. Gall, Irina A. Afonina, Michael J. Singer, Nicolaas M.J. Vermeulen
  • Patent number: 6660845
    Abstract: The invention provides compositions and methods for improved hybridization analysis utilizing DNA, RNA, PNA and chimeric oligomers in which one or more purine bases are substituted by a pyrazolo[5,4-d]pyrimidine or by a 7-deazapurine purine analogue. Reduced self-aggregation and reduced fluorescence quenching are obtained when the oligomers are used in various methods involving hybridization. Methods of synthesis, as well as novel synthetic precursors, are also provided.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: December 9, 2003
    Assignee: Epoch Biosciences, Inc.
    Inventors: Alexander A. Gall, Igor V. Kutyavin, Nicolaas M. J. Vermeulen, Robert O. Dempcy
  • Publication number: 20030224359
    Abstract: Modified oligonucleotides are provided containing bases selected from unsubstituted and 3-substituted pyrazolo[3,4-d]pyrimidines and 5-substituted pyrimidines, and optionally have attached minor groove binders and reporter groups.
    Type: Application
    Filed: December 21, 2001
    Publication date: December 4, 2003
    Applicant: Epoch Biosciences, Inc.
    Inventors: Robert O. Dempcy, Alexander A. Gall, Sergey G. Lokhov, Irina A. Afonina, Michael J. Singer, Igor V. Kutyavin, Nicolaas M.J. Vermeulen
  • Patent number: 6653473
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: November 25, 2003
    Assignee: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M. J. Vermeulen
  • Publication number: 20030170872
    Abstract: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs.
    Type: Application
    Filed: August 21, 2002
    Publication date: September 11, 2003
    Applicant: Koronis Pharmaceuticals, Inc.
    Inventors: Ling Li, Alexander Gall, Richard Daifuku
  • Publication number: 20030096254
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Application
    Filed: March 29, 2002
    Publication date: May 22, 2003
    Applicant: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
  • Publication number: 20030008304
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Application
    Filed: February 26, 2002
    Publication date: January 9, 2003
    Applicant: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
  • Publication number: 20020155484
    Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about 300 to about 800 nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyidiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10-[phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H,3H,7H,9H,10H)-tetrone structure.
    Type: Application
    Filed: March 7, 2002
    Publication date: October 24, 2002
    Applicant: EPOCH PHARMACEUTICALS, INC.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
  • Publication number: 20020034754
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Application
    Filed: June 6, 2001
    Publication date: March 21, 2002
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
  • Patent number: 6312953
    Abstract: Chemically modified oligonucleotides (ODNS) are complementary, either in the sense of the classic “four letter code” recognition motif, or in the sense required for triple strand formation based on the more limited “two letter code recognition motif”, to a target sequence of double stranded DNA of an invading cell, organism or pathogen, such as a virus, fungus, parasite, bacterium, malignant cell, or any duplex DNA which is desired to be broken into segments for the purpose of “mapping”. The ODNs have cross-linking agents covalently attached at least to two different sites of the ODN. Alternatively, the cross-linking agent which is attached to one site on the ODN has two cross-linking functionalities, and therefore in effect comprises two cross-linking agents.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: November 6, 2001
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Igor V. Kutyavin, Alexander A. Gall
  • Patent number: 6143877
    Abstract: A triplex forming oligonucleotide is complementary pursuant to the G/T or A/G recognition motif to a homopurine, or substantially homopurine target sequence in double stranded nucleic acids, and at least one and preferably all of the guanine bases are replaced by their pyrazolo[3,4-d]pyrimidine analog, namely by 6-amino-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one. The oliginucleotides containing the pyrazolo[3,4-d]pyrimidine analog of guanine exhibit a lesser degree of self-association, and lack the nucleophilic nitrogen atom in the 7 position of guanine. The latter feature results in a diminished extent of self-crosslinking in ODNs which also have a covalently attached cross-linking agent.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: November 7, 2000
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Alexander Gall, Igor V. Kutyavin
  • Patent number: 6136601
    Abstract: A method for introducing a site-specific mutation into a target polynucleotide sequence is presented. The method involves the use of an oligonucleotide capable of binding to the target sequence, either by triplex formation (mediated by Hoogsteen, reverse Hoogsteen or equivalent base pairing) or by Watson/Crick base pairing (in the presence of a recombinase enzyme). The oligonucleotide of the invention is modified by the covalent attachment of one or more electrophilic groups. When a modified oligonucleotide is bound to its target sequence, the electrophilic group is able to interact with a nearby nucleotide in the target sequence, causing a modification to the nucleotide that results in a change in nucleotide sequence. Compositions used in the practice of the method are also disclosed.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: October 24, 2000
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Igor V. Kutyavin, Alexander A. Gall